The drug MingJuno acquires Syracuse plus-code solid tumor T cell immunotherapy development.

On July 20, the company announced the completion of its acquisition of Syracuse Biopharma (Hong Kong) Co., Ltdand obtained a license for EUreka Therapeutics' proprietary ARTEMIS ® antibody TCR technology for solid tumors in China and Southeast Asian countriesdetails ofacquisition were not disclosedDrLiu Cheng, founder and CHIEF executive officer of Ureko Bio, will join the board of directors of Yurico, and Victor Shum, Chief Commercial Officer and General Counsel of Ureco, will become an observer of the boardUrico Bio, a biopharmaceutical company dedicated to the development of new T-cell therapies for solid tumors, the company developed a rich and innovative T-cell immunotherapy pipeline for a wide range of solid and hematomas using two core technology platforms, the ArtEMIS ® AbTCR platform and the E-ALPHA ® Antibody Screening, the solid tumor for liver cancer is mainly in the research project ET140202 has entered the phase 1/2 multicenter clinical phase in the United StatesSyracuse Biopharma was established in 2017 by Ureco Bio, which is dedicated to the development and commercialization of Urico's proprietary antibody screening technology platform in China and ASEAN countriescurrent clinical projects include the ARTEMIS ® clinical program for the treatment of common types of liver cancer liver cell carcinoma (HCC) at AFP"We are honored to receive the recognition of the value of ARTEMIS ® technology platform by the leader in China's cell immunotherapy industry, with our common enthusiasm and sense of urgency, to develop innovative cell immunotherapy for cancer patients," drLiu saidin China, the incidence of liver cancer is very highthe company's extensive expertise has focused on the development of innovative therapies that allow patients to benefit as early as possibleFounded in 2016," Is a clinically innovative biopharmaceutical company focused on the development, transformation and application of cell immunotherapy public information shows that the drug Ming Juno China has established a mature and stable process system and the international leading cGMP production quality management system, and obtained China's first CD19 target CAR-T cell treatment products IND clinical approval (four indications, clinical trials 1, 2), but also in China to carry out clinical research under the IND batch of the largest number of patients in the research products since 2020, the drug has seen a number of significant advances On June 9, , the company announced that it had completed a $100 million round B financing the company has so far completed more than $200m in financing, including Round A and B at the same time, the company's CD19-targeted CAR-T therapeutic product Serkirunsai injection (tentative) in China's listing application on June 30 this year by the State Drug Administration of China (NMPA) to accept just a few days ago, the drug has reached an exclusive priority licensing agreement with Acepodia, a U.S biotech company, to obtain exclusive priority licensing for clinical and commercialization in Chinese mainland, Hong Kong and Macau, the latter's two cell immunotherapy candidates, ACE1702 and ACE1655 's completion of the acquisition of Syracuse Biopharma (Hong Kong) Limited is another important milestone in the company's development "We are pleased to announce the completion of the acquisition of Syracuse to further expand our clinical research into cell therapy for solid tumors, particularly liver cancer," said Yiping Li, co-founder and CEO of Drug Syracuse Syracuse and Ureco have developed unique TCR-mimic and ARTEMIS ® technologies for the treatment of solid tumors we look forward to working with the team to provide patients with a whole new generation of T-cell immunotherapy "